Navigation Links
Eltrombopag effective for hepatitis C patients with low blood-platelet counts
Date:12/28/2007

NEW YORK (Dec. 28, 2007) -- For patients with hepatitis C, having a low blood platelet count is a frequent complication associated with advanced disease. This problem is compounded by the fact that standard antiviral treatment for the disease can further reduce platelet numbers to dangerously low levels, effectively denying these patients the treatment they urgently need. Now, research published in the New England Journal of Medicine finds that a new drug, eltrombopag, appears to significantly boost platelet counts, opening the door to effective treatment.

"In this study, eltrombopag increased platelet counts in a dose-dependent manner, allowing more patients to complete the first 12 weeks of antiviral therapy -- an important treatment goal," says Dr. Samuel Sigal, who led the study at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City -- one of 22 study sites.

Dr. Sigal is assistant professor of medicine in the Division of Gastroenterology and Hepatology at Weill Cornell Medical College and assistant attending hepatologist in the Center for Liver Diseases and Transplantation at NewYork-Presbyterian/Weill Cornell.

The Phase 2 placebo-controlled study followed 74 patients with low platelet counts and cirrhosis of the liver due to hepatitis C virus (HCV) infection. Seventy-four percent of those randomized to take the lowest dose (30 milligrams daily) saw their platelet counts go up significantly, while 79 percent and 95 percent of the participants saw increases with the higher doses (50 or 75 milligrams daily, respectively). And, 12 weeks of antiviral therapy were completed by 36, 53 and 65 percent of patients at the three dose levels -- with increased numbers matched to the size of the dose. Underlining the trend, less than a quarter of patients receiving placebo completed their therapy.

The study identified side effects -- including headaches, dry mouth, abdominal pain and nausea. None were serious enough
'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

1

GOOD

Page: 1 2 3

Related biology news :

1. Gamma globulin effective in treating eye infections caused by adenoviruses
2. UC health news: molecular pathway may predict chemotherapy effectiveness
3. Socioeconomic position associated with effectiveness of HIV drugs
4. New nanoparticle vaccine is more effective but less expensive
5. MIT model could improve some drugs effectiveness
6. Trial seeks genetic fingerprint for predicting drug effectiveness
7. New hope for horse lovers as effective control for killer ragwort is proposed
8. Quantitative PET imaging finds early determination of effectiveness of cancer treatment
9. Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
10. Tamiflu effective for treatment and prevention of influenza in children 1 year and older
11. Safe and effective therapy discovered for patients with protein-losing enteropathy

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...possess an ingenious mechanism for preventing oxyg...his is the new finding of a team of biologists tha...esearch institute in Flanders, Belgium, connected ...made this discovery by modifying the DNA of the in... this model organism, they have uncovered the exis...
(Date:11/20/2009)...COPD), a respiratory disease commonly known as chr...g cause of death worldwide. 600 million people li...d any real treatment or cure, Grace Parraga of Rob...rn Ontario in London, Canada, is using various ima...se. , Parraga is a scientist in the Imaging ...
(Date:11/19/2009)...al with an unwieldy name: 4-hydroxybutyrate (4-HB)...te-rape drug. , Now, a team of Ohio and Michiga...-HB is metabolized by the body. "This is new and i...fessor and chair of biological sciences at Michiga...earch team. "It may provide new clues on how to c...
Breaking Biology News(10 mins):Biologists discover bacterial defense mechanism against aggressive oxygen 2Gaining a better picture of lung disease 2Researchers begin to decipher metabolism of sexual assault drug 2SHPS Receives Re Accreditation from URAC for Multiple Health Management Programs 48486 1SHPS Receives Re Accreditation from URAC for Multiple Health Management Programs 48486 2Studies Report More Harmful Effects From BPA 48481 1Studies Report More Harmful Effects From BPA 48481 2Studies Report More Harmful Effects From BPA 48481 3Preliminary report on antidepressants published 48477 1Preliminary report on antidepressants published 48477 2
... is available in German . , The coal tit appear...n stay together for their whole lives. That,s only...op ten two-timers worldwide. That is what research...r this they have taken genetic fingerprints from m...this way they were able to identify the biological...
...in her lab showed that mate (mah tā) tea drin... activity of an enzyme that promotes HDL (good) ch...iversity of Illinois scientist Elvira de Mejia hea...d taken medicinally for centuries. , She returned...rs of La Universidad Nacional de Misiones (UNaM) t...
.... By most measures of an academic medical centers...hip, fiscal year 2007 was a banner year for Oregon...disclosed 132 inventions, more than in any previou...e number in 2000. , Five new startup companies ... the year, bringing the total to 33 since 2000 and...
Other Biology News:Age increases chance of success as two-timer 2Age increases chance of success as two-timer 3More on mate tea: lower cholesterol and an international agreement 2OHSU turns innovations into commercial opportunities at record pace 2OHSU turns innovations into commercial opportunities at record pace 3OHSU turns innovations into commercial opportunities at record pace 4OHSU turns innovations into commercial opportunities at record pace 5
(Date:11/20/2009)...0 Veridiam (www.veridiam.com) won ...any category at the 2009 Workplace Excellence Awar...ety for Human Resources Management and recognize i...s. ,, Veridiam was one of nine winners, selecte... honored at the recent awards ceremony. San Diego-...
(Date:11/20/2009)...TTLER TOLEDO recently announced that a free webina...Using At-Line Particle Characterization”, wi...nar, the application of in situ particle character...d optimize a series of roller compaction runs whil...mpaction forces. , (PRWEB...
(Date:11/19/2009)...ov. 19 Dr. Mate Hidvegi, inventor ...o a press release issued on November 17 by Biropha...king false and self-serving statements about its U...dvegi stated from his office in Budapest, Hungary:...mar does not apply to AveULTRA, www.aveultra.com...
(Date:11/19/2009)...ermany, November 19 MONITORING FOR... 16th, 2009 Flibanserin in the,indication treatmen...n,s,disease for orphan drug status designation wit...nduced dyskinesia is a complication of the mainsta...burden to some of those,affected, since it may be ...
Breaking Biology Technology:Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category 2Roller Compaction Process Optimization Using At-Line Particle Characterization 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
...TCH (Taxotere, Carboplatin, Herceptin) showed a si...DFS) and Overall Survival (OS), compared to AC-T,(...axel) and a 5-fold lower, cardiotoxicity compare... adjuvant therapy for HER2-positive E...tional,Research Group (CIRG), a division of TRIO (...
...RICHMOND, Calif., May 29 Sangamo BioSciences,Inc....hier, Sangamo,s,president and CEO, will provide an...at 1:40 p.m. (ET) on Friday, June 6, 2008, at the ... San Francisco., The presentation will be webcast...o BioSciences website in the Investor Relations se...
...SWARTZ CREEK, Mich., May 29 Diplomat Specialty,Ph...isease management (DM),and drug therapy management...cy was one of 3 sponsors of the National Managed C...Texas. This forum brought 30 industry,executives f...together to,review and improve on the current offe...
Other Biology Technology:First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA 2First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA 3First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA 4Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference 2Diplomat Specialty Pharmacy Sponsors National Managed Care Roundtable for Industry Executive Advisory Board 2
...and miRNA Isolation Traditional mRNA isolation pr... and can result in the loss of substantial amounts...t purifies all RNA species (including small RNAs),...chment procedure included in the mirVana miRNA Iso...
...AD: 5B15-5B-11E. Immunogen: Synthetic peptide der...rotein. Specificity: Specific for the internal r...entifies the target band at ~590 kDa. Reactivity:...d media from primary tracheobranchial epithelial c...
GIBCO Keratinocyte-SFM (1X) liquid from Invitrogen
Rabbit Anti-LSD1 / BHC110 Antibody, Unconjugated from Upstate
Biology Products: